Clinical Trial Update: Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial of rasagiline for prodromal Parkinson disease, including REM sleep behavior disorder, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Rem Sleep Behavior Disorder
• Synucleinopathies

Drugs mentioned

• Azilect (rasagiline)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: REM Sleep Behavior Disorder, Parkinson Disease | Phase 2, Phase 3 | Status: WITHDRAWN